ADVERTISEMENT
Biocon Q1 Results Review - New Launches Critical To Revive Growth: ICICI Securities
The company's Ebitda margin is likely to remain under pressure and hover around ~21–22% with curbs in biosimilars margins and India business divestment, says the brokerage.
12 Aug 2024, 01:39 PM IST 
%20Syngene%20is%20a%20subsidiary%20of%20Biocon%20Ltd..jpg?rect=0%2C849%2C8153%2C4586&auto=format%2Ccompress&fmt=avif&mode=crop&ar=16%3A9&q=60)
Technician using a pipette testing a solution inside chemistry lab at Syngene International Ltd. (Source:Company) Syngene is a subsidiary of Biocon Ltd.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
